Unlike secondary mitral regurgitation (MR) in the setting of left ventricular (LV) disease, the
occurrence of functional MR in atrial fibrillation (AF) and/or heart failure with preserved …

The development of secondary mitral regurgitation (MR) due to left ventricular dysfunction,
also known as functional MR, is strongly associated with a poor prognosis in patients with …

Background: The morbidity and mortality of patients with functional mitral regurgitation (MR)
remain high, but no pharmacological therapy has been proven effective. The hypothesis of …

Mitral regurgitation affects more than 2 million people in the USA. The main causes are
classified as degenerative (with valve prolapse) and ischaemic (ie, due to consequences of …

Secondary (or functional) mitral regurgitation (SMR) occurs frequently in chronic heart failure
(HF) with reduced left ventricular (LV) ejection fraction, resulting from LV remodelling that …

Objective To clarify whether any particular β blocker is superior in patients with heart failure
and reduced ejection fraction or whether the benefits of these agents are mainly due to a …

Background Beta‐blockers and inhibitors of the renin‐angiotensin‐aldosterone system
improve survival and reduce morbidity in people with heart failure with reduced left …

Left atrial (LA) structural and functional remodeling reflects a spectrum of pathophysiological
changes that have occurred in response to specific stressors. These changes include …

The aim of the present study was to determine whether the risk of mortality associated with
the concentration of soluble ST2 (sST2) differs in patients with acutely decompensated heart …

Aims Atrial fibrillation (AF) is an important morbidity–mortality risk factor, especially in
patients with heart failure (HF). Beta-blockers reduce morbidity and mortality in HF. The …